

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

JUL 24 2003

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	09/870,089
Filing Date	May 30, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket No.	GZ 2099.00

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
JC4	1	TSUJIMOTO, A. et al. "Isolation of cDNA-Binding Proteins Which Specifically Bind to a Tax-Responsive Enhancer Element in the Long Terminal Repeat of Human T-Cell Leukemia Virus Type I" (1991) J. Vir. 65(3):1420-1426	
JUL 24 2003	2	KARPINSKI, B.A. et al., "Molecular Cloning of Human Creb-2: An ATF/CREB Transcription Factor that can Negatively Regulate Transcription from the camp Response Element" P.N.A.S. (1992) 89:4820-4824	
	3	EMBL Online, Accession No. M86842	
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		
	19		
	20		
	21		
	22		
	23		
	24		
	25		
	26		
	27		

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

Examiner's Signature

Date

Considered

12/23/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS  
ORIGINALLY FILED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

14B  
#14  
Complete if Known

Substitute for form 1449A-PTO

JUL 24 2002

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	09/870,089
Filing Date	May 30, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket No.	GZ 2099.00

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GNL	1	US-5,688,657	11-18-97	Tsang, et al.	
	2				
	3				
	4				
	5				
	6				
	7			AUG 14 2002	
	8				JUL 26 2002
	9			TECH CENTER 1600/2900	
	10			TECH CENTER 1600/2900	

RECEIVED  
RECEIVED  
AUG 14 2002  
JUL 26 2002  
TECH CENTER 1600/2900  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	11					
	12					
	13					
	14					
	15					
	16					

Examiner's  
SignatureDate  
Considered


12/23/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS  
ORIGINALLY FILED



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

72b/10101 for form 1449B-PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 1

<i>Complete if Known</i>	
Application Number	09/870,089
Filing Date	May 30, 2001
First Named Inventor	Nicolette
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	GZ 2099.00

#### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

EXAMINER'S ROLL CALL - NON-PATENT LITERATURE DOCUMENTS		T <sup>2</sup>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
Gu	1	Tsujimoto, A., et al.: "Isolation of CDNAS for DNA-Binding Proteins which Specifically Bind to a Tax-Responsive Enhancer Element in the Long Terminal Repeat of Human T-Cell Leukemia Virus Type I" Journal of Virology, New York, US, US, Vol. 65, No. 3, March 1991 (1991-03), pages 1420-1426.
Gu	2	Mielnicki, et al.: "Mutated Atf4 Suppresses c-Ha-ras Oncogene Transcript Levels and Cellular Transformation in NIH3T3 Fibroblasts" Biochemical and Biophysical Research Communications, Vol. 228, 1996, pages 586-595.
	3	
	4	
	5	
	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	
	20	
	21	
	22	
	23	
	24	
	25	
	26	

RECEIVED  
FEB 26 2003  
TECH CENTER 1600/2900

Examiner's Signature		Date Considered	12/23/03
-------------------------	---	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/810,089
Filing Date	May 30, 2001
First Named Inventor	Nicolette
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	GZ 2099.00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	1	US-			
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)				
gn	8	WO 99/54353-A	10-28-99	Schmitt	Pgs. 1-4; Seq. 48	
	9	WO 00/55174-A	09-21-00	Human Genome Sciences	Page 3	
	10	WO 01/57271-A	08-09-01	Wensheng	Page 6; Seq. 12165	
✓	11	WO 01/92306-A	12-06-01	Genzyme	entire doc.	
	12					
	13					
	14					
	15					
	16					
	17					
	18					
	19					
	20					
	21					

Examiner's Signature	<i>1</i>	Date Considered	<i>12/23/03</i>
----------------------	----------	-----------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED  
EUROPEAN CENTER 1600 PCTO  
FEB 26 2003



Form PTO-1449		Docket No. 126881209900	Appl. No. 09/870,080 <i>Sm</i>
INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>		Applicant(s) Charles A. NICOLETTE	
		Filing Date: May 30, 2001	Group Art Unit: Unassigned

## U.S. PATENT DOCUMENTS

 RECEIVED  
AUG 13 2001

TO 1700

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
<i>Guy</i>	1.	07/28/87	4,683,195	Mullis et al.			
	2.	07/28/87	4,683,202	Mullis			
	3.	06/28/88	4,754,065	Levenson et al.			
	4.	01/24/89	4,800,159	Mullis et al.			
<i>↓</i>	5.	08/08/95	5,440,013	Kahn			
	6.	11/17/98	5,837,249	Heber-Katz et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
<i>Sue</i>	7.	08/01/96	WO 96/23060	The Government of the United States of America	—	—	

## OTHER DOCUMENTS

*(including author, title, date, pertinent pages, etc.)*

Examiner Initials	Ref. No.	Title
<i>Sue</i>	8.	Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) <i>Science</i> 274(5284):94-96
	9.	Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) <i>J. Immunol.</i> 161:4447-4455
	10.	Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) <i>J. Exp. Med.</i> 184:465-472
	11.	Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) <i>PNAS USA</i> 86:6748-6752
	12.	Carter, B.J., "Adeno-associated virus vectors" (1992) <i>Curr. Op. Biotechnol.</i> 3:533-539
	13.	Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) <i>Cytometry</i> 27:71-76
	14.	Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) <i>PNAS USA</i> 86:8912-8916
	15.	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) <i>Molec. Med. Today</i> 3:261-268
	16.	Culver, K. et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) <i>PNAS USA</i> 88:3155-3159
<i>✓</i>	17.	Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) <i>Acta. Cryst. C48:1239-1241</i>

EXAMINER: <i>Sm</i>	DATE CONSIDERED: <i>12/17-3/03</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-1449		Docket No. 126881209900	Appl. No. 09/870,089 <i>See</i>																																																				
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	<i>RECEIVED</i> AUG 14 2001 TC 1700																																																				
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned																																																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 5%; text-align: center;"><i>See</i></td> <td style="width: 15%;">18.</td> <td>Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> <b>42</b>(1):68-77</td> </tr> <tr> <td rowspan="3" style="width: 5%; vertical-align: top; text-align: center;">/</td> <td>19.</td> <td>DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i>(9):1687-1689</td> </tr> <tr> <td>20.</td> <td>Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> <b>47</b>:1-8</td> </tr> <tr> <td>21.</td> <td>Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> <b>57</b>:285-320</td> </tr> <tr> <td colspan="3">22. Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> <b>160</b>:181-189</td> </tr> <tr> <td colspan="3">23. Garvey D.S. et al., "3,4-disubstituted <math>\gamma</math>-lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> <b>55</b>(3):936-940</td> </tr> <tr> <td colspan="3">24. Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> <b>31</b>:189-199</td> </tr> <tr> <td colspan="3">25. Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> <b>268</b>:249-262</td> </tr> <tr> <td colspan="3">26. Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> <b>181</b>:375-380</td> </tr> <tr> <td colspan="3">27. Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> <b>29</b>(31):3853-3856</td> </tr> <tr> <td colspan="3">28. Kahn, M. and S. Bertenshaw, "The incorporation of <math>\beta</math>-turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> <b>30</b>(18):2317-2320</td> </tr> <tr> <td colspan="3">29. Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> <b>5</b>(9):2377-2385</td> </tr> <tr> <td colspan="3">30. Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> <b>91</b>(9):3515-3519</td> </tr> <tr> <td colspan="3">31. Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of <math>\alpha,\beta</math>-dimethyl-phenylalanine and <math>\alpha,\beta</math>-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> <b>32</b>(41):5769-5772</td> </tr> <tr> <td colspan="3">32. Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> <b>113</b>:2275-2283</td> </tr> <tr> <td colspan="3">33. Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent <math>\beta</math>-turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> <b>50</b>:5834-5838</td> </tr> <tr> <td colspan="3">34. Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones <math>^1</math>H NMR evidence for <math>\beta</math>-sheet formation" (1988) <i>Tetrahedron Lett.</i> <b>29</b>(40):5081-5082</td> </tr> <tr> <td colspan="3">35. Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L-<math>\alpha</math>, <math>\gamma</math>-diaminobutyric acid and D-glutamic acid: A <math>\beta</math>-turn template" (1988) <i>Tetrahedron Lett.</i> <b>29</b>(40):5057-5060</td> </tr> </table>				<i>See</i>	18.	Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> <b>42</b> (1):68-77	/	19.	DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689	20.	Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> <b>47</b> :1-8	21.	Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> <b>57</b> :285-320	22. Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> <b>160</b> :181-189			23. Garvey D.S. et al., "3,4-disubstituted $\gamma$ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> <b>55</b> (3):936-940			24. Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> <b>31</b> :189-199			25. Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> <b>268</b> :249-262			26. Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> <b>181</b> :375-380			27. Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (31):3853-3856			28. Kahn, M. and S. Bertenshaw, "The incorporation of $\beta$ -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> <b>30</b> (18):2317-2320			29. Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> <b>5</b> (9):2377-2385			30. Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> <b>91</b> (9):3515-3519			31. Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of $\alpha,\beta$ -dimethyl-phenylalanine and $\alpha,\beta$ -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> <b>32</b> (41):5769-5772			32. Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> <b>113</b> :2275-2283			33. Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent $\beta$ -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> <b>50</b> :5834-5838			34. Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones $^1$ H NMR evidence for $\beta$ -sheet formation" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (40):5081-5082			35. Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- $\alpha$ , $\gamma$ -diaminobutyric acid and D-glutamic acid: A $\beta$ -turn template" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (40):5057-5060		
<i>See</i>	18.	Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> <b>42</b> (1):68-77																																																					
/	19.	DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689																																																					
	20.	Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> <b>47</b> :1-8																																																					
	21.	Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> <b>57</b> :285-320																																																					
22. Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> <b>160</b> :181-189																																																							
23. Garvey D.S. et al., "3,4-disubstituted $\gamma$ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> <b>55</b> (3):936-940																																																							
24. Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> <b>31</b> :189-199																																																							
25. Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> <b>268</b> :249-262																																																							
26. Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> <b>181</b> :375-380																																																							
27. Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (31):3853-3856																																																							
28. Kahn, M. and S. Bertenshaw, "The incorporation of $\beta$ -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> <b>30</b> (18):2317-2320																																																							
29. Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> <b>5</b> (9):2377-2385																																																							
30. Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> <b>91</b> (9):3515-3519																																																							
31. Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of $\alpha,\beta$ -dimethyl-phenylalanine and $\alpha,\beta$ -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> <b>32</b> (41):5769-5772																																																							
32. Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> <b>113</b> :2275-2283																																																							
33. Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent $\beta$ -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> <b>50</b> :5834-5838																																																							
34. Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones $^1$ H NMR evidence for $\beta$ -sheet formation" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (40):5081-5082																																																							
35. Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- $\alpha$ , $\gamma$ -diaminobutyric acid and D-glutamic acid: A $\beta$ -turn template" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (40):5057-5060																																																							
EXAMINER: <i>See</i>	DATE CONSIDERED: <i>12/23/03</i>																																																						
EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.																																																							



RECEIVED  
AUG 14 2001  
TC 1700

Form PTO-1449		Docket No. 126881208900	Appl. No. 09/876,636
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned
36.	Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 <sup>4,8</sup> ]ridecene, 1 the preferred conformation of 1 (1=αtemp-OH) and its peptide conjugates αtemp-L-(Ala) <sub>n</sub> -OR (n=1 to 4) and α-temp-L-Ala-L-Phe-Lys(εBoc)-L-Lys(ε-Boc)-NHMe studies of templates for α-helix formation" (1988) <i>Tetrahedron Lett.</i> <b>29</b> (39):4935-4938		
37.	Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ-turn templates" (1989) <i>J. Org. Chem.</i> <b>54</b> :109-115		
38.	McGroarty, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) <i>Virology</i> <b>163</b> :614-617		
39.	Merrifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) <i>Recent Progress in Hormone Res.</i> <b>23</b> :451-482		
40.	Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) <i>J. Takeda Res. Labs.</i> <b>43</b> (3/4):53-76		
41.	Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) <i>PNAS. USA</i> <b>90</b> :2443-2447		
42.	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) <i>Curr. Top. Microbiol. Immunol.</i> <b>158</b> :97-129		
43.	Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of β-turn central part" (1985) <i>Tetrahedron Lett.</i> <b>26</b> (5):647-650		
44.	Nair, S. et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) <i>J. Exp. Med.</i> <b>175</b> :609-612		
45.	Olson, G.L. et al., "Design and synthesis of a protein β-turn mimetic" (1990) <i>J. Am. Chem. Soc.</i> <b>112</b> :323-333		
46.	Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) <i>J. Exp. Med.</i> <b>183</b> :317-322		
47.	Pardoll, D.M., "Cancer vaccines" (1998) <i>Nature Med.</i> <b>4</b> (5 Suppl.):525-531		
48.	Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) <i>J. Immunol.</i> <b>149</b> (11):3580-3587		
49.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class 1 Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> <b>14</b> :34-57		
50.	Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) <i>J. Immunol.</i> <b>157</b> :2539-2548		
51.	al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) <i>J. Immunol.</i> <b>155</b> (2):662-673		
52.	Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) <i>Blood</i> <b>79</b> (10):2694-2700		
53.	Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) <i>J. Virol.</i> <b>68</b> (9):5685-5689		
54.	Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) <i>Int. J. Cancer</i> <b>85</b> :829-838		
55.	Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted		

EXAMINER:	DATE CONSIDERED: 12/23/03
EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

RECEIVED

AUG 14 2001

TC 1700

Form PTO-1449		Docket No. 126881209900	Appl. No. 09/870,086
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned
<p>conformation" (1990) <i>Int. J. Peptide Protein Res.</i> 35:501-509</p> <p>56. Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) <i>Curr Opin Biotechnol.</i> 10(5):434-439</p> <p>57. Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" (1994) <i>J. Immunol.</i> 153(12):5586-5592</p> <p>58. Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) <i>J. Immunol.</i> 154:2733-2742</p> <p>59. Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) <i>Int. Immunol.</i> 7(4):653-663</p> <p>60. Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) <i>J. Immunol. Meth.</i> 209(1):25-36</p> <p>61. Tanguay, S. and J.J. Killion, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) <i>Lymphokine Cytokine Res.</i> 13(4):259-263</p> <p>62. Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) <i>J. Immunol.</i> 164(2):1125-1131</p> <p>63. van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) <i>J. Immunol.</i> 156:3308-3314</p> <p>64. Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) <i>J. Immunol.</i> 131(3):1312-1317</p> <p>65. Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) <i>Anal. Biochem.</i> 171:1-32</p> <p>66. Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) <i>Nat. Med.</i> 5(7):823-827</p> <p>67. Zabrocki, J. et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) <i>J. Am. Chem. Sci.</i> 110:5875-5880</p> <p>68. Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) <i>Int. J. Pep. Protein Res.</i> 38(2):131-138</p> <p>69. Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) <i>J. Immunol.</i> 161(4):1705-1709</p> <p>70. Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) <i>J. Immunol.</i> 150(5):1763-1771</p>			

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED: <i>12/23/03</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

**COPY OF PAPER  
ORIGINALLY FILED**

PTO/SB/08 (2/92)  
Sheet 1 of 1

~~RECEIVED~~

APR 25 2002

~~TECH CENTER 1600/2900~~

EXAMINER: *[Signature]* DATE CONSIDERED: *1/22/2013*  
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.